Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Clinical Update
Japanese Encephalitis (JE) Vaccine for US Children

JE Vaccines in the United States

Inactivated Vero cell culture–derived JE vaccine (JE-VC, Ixiaro) is the only JE vaccine that is licensed and available in the United States. JE-VC is manufactured by Intercell Biomedical (Livingston, United Kingdom) and is distributed in the United States by Novartis Vaccines (Cambridge, Massachusetts). In 2009, the Food and Drug Administration (FDA) licensed JE-VC for use in adults ≥17 years of age. In May 2013, FDA licensed JE-VC for use in children 2 months through 16 years of age. On June 19, 2013, CDC’s Advisory Committee on Immunization Practices (ACIP) voted to extend existing recommendations for use of JE vaccine to include use of JE-VC in children aged 2 months through 16 years.  ACIP recommendations for prevention of JE and the use of JE vaccine are available on the CDC ACIP webpage.

Vaccine Administration

The primary series for JE-VC is 2 doses administered 28 days apart:

  • For adults and children aged ≥3 years, each dose is 0.5 mL.
  • For children aged 2 months through 2 years, each dose is 0.25 mL. To administer a 0.25-mL dose, health care providers must expel and discard half of the volume from the 0.5-mL prefilled syringe before injection. To enable this, the manufacturer is developing a prefilled syringe with a red line on the barrel to indicate the 0.25-mL point.

JE-VC product information is available at the FDA Ixiaro webpage.

More Information